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INTRODUCTION
Spinal cord injury 
Spinal cord injury (SCI) is an disabling disease caused in prevalence by a traumatic event against
the spine, leading to a partial or total loss of conduction of nervous stimuli downstream of the
injury site. From a pathophysiological point of view, it is possible to identify two main events that
occur to define the damage: the first is defined as “primary damage”, deriving from the trauma
and consisting in a contusion, compression or a laceration of the spinal cord, that results in a
breaking of blood-brain barrier, ischaemia, necrosis of damaged cells; afterwards the “secondary
damage” raises, including the inflammatory reaction of the lesioned tissue, as the releasing of
toxic  chemicals  from  necrotic  cells  and  from  activated  immune  cells,  electrolytes  unbalance,
glutamate  release,  apoptosis  of  cells  not  directly  involved  in  the  primary  damage,  massive
demyelination, hypoperfusion (McDonald JW and Sadowsky C, 2002).Later, the scar formation and
epigenetic  alterations  determine the creation of  a  “non-permissive” environment towards  the
regenerations of nerve fibers (Cox A et al., 2014), thus increasing the initial damage, resulting in
loss of fibers conductivity and finally in a partial or total loss of function.
Figure 1: Events contributing to damage formation in SCI (from Cox A. et al., 2014)
So  far  the  pharmacological  treatment  is  based  on  steroids  administration,  especially
methylprednisolone sodium succinate  (MPSS),  in  order  to  achieve an  overall  reduction of  the
inflammatory processes that cause the secondary damage (Baptiste DC and Fehlings MG, 2006).
There are evidences that MPSS is able to decrease the edema formation, reactive oxygen species
(ROS)  release  and  neural  degeneration  if  administered  by  8  hours  from  the  traumatic  event
(Bracken  MB  et  al.,  1990,  Anderberg  L  et  al.,  2007).  However  the  use  of  MPSS  raises  some
concerns  because  of  its  adverse  effects,  like  hyperglycemia,  massive  immunodepression,  and
sepsis (Bracken MB et al., 1990; Bracken MB et al., 1997). Furthermore recent studies showed the
beneficial  effects  of  inflammation,  especially  for  its  pro-regenerative  role:  macrophages  and T
lymphocytes are known to elicit neuroregeneration by releasing neurotrophic factor (La Fleur M et
al., 1996; Jameson  J et al., 2002, Yin Y et al., 2006). Macrophages can also modulate the activity of
T-lymphocytes,  particularly  after  myelin  debris  removal  (Bogie  J  et  al.,  2011),  with  an  overall
reduction of inflammation.  Moreover it  is  known that the secondary phase of inflammation is
fundamental for promoting a morpho/functional recovery (Beck KD et al., 2010; Baptiste  DC and
Fehlings  MG, 2006) in SCI. 
Due  to  all  these  concerns  and  to  ensure  patients  the  best  therapies,  others  therapeutic
approaches were taken into account, trying to treat all the different aspects of secondary damage.
Over the past 20 years few clinical trials were undertaken, designed to assess the clinical feasibility
and the  safety  of  novel  compounds.  Nevertheless  some of  the studies  showed a  therapeutic
efficacy for these molecules, albeit potential and still to be fully proven in order to be used in
clinical.
Aminosteroids
Aminosteroids, also called  lazaroids, are chemical compounds analogs to glucocorticoids able to
decrease lipid peroxidation with no activity on steroid receptors. They could potentially be used in
reducing  tissue  damage  without  eliciting  the  side  effect  of  direct  stimulation  of  the  steroids
pathway.
Lazaroids exert their beneficial effects via stabilization of the plasma membrane and neutralizing
free radicals: in animal models of traumatic hypoxia/reperfusion, Tirilazad mesylate (TM) was able
to limit  the damage  acting directly against  free radicals  and preserving vitamin E (a  powerful
antioxidant) (Hall  ED et al., 1989; Sato PH et al., 1992).
Lazaroids are also effective in stabilizing plasma membrane: due to their chemical properties they
are incorporated into the lipid bilayer reducing in loco lipid peroxidation (Hall ED et al., 1994). 
Regarding these positive effects of Tirilazad, its use in clinical protocols is questionable, as some
concerns raised following clinical  studies.   In  NASCIS  III  the effects of  Tirilazad mesylate  were
compared  to  diverse  MPSS  administrations,  showing  the  same  efficacy  of  a  48h  MPSS
administration in treating SCI, though with less adverse effects. However, after 6 months patients
treated  with methylprednisolone had a  better  outcome compared to TM (Bracken MB et  al.,
1997).
In another trial the use of Tirilizad did not exert any beneficial effect to patients with head injury
(Marshall LF et al., 1998), or subarachnoid hemorrhage (Zhang S et al., 2010). In conclusion, there
is  no clinical  evidence supporting use of  TM in SCI,  although further studies are necessary to
elucidate the potentiality linked to the use of lazaroids as a clinical therapy.  
Gangliosides
Gangliosides  are  sialic-acid  containing  glicosphingolipids  present  in  great  abundance  in  the
nervous system. Here they locate in the outer part of the plasma membrane of cells, where they
form clusters important for lipid rafts architecture and functions (Simons K and Toomre D, 2000;
Furukawa K. et al., 2011). Biologically, gangliosides have a role in differentiation and cell growth,
intracellular trafficking and in regulating the effects of neurotransmitters and neurotrophic factors
(Prendergast J et al., 2014). Deficits in their production or metabolism could lead to neurological
deficit and neurodegeneration (van den Berg B et al., 2014; Toshio Ariga 2014; Furukawa K et al.,
2011).
The first trial using gangliosides was the Maryland GM1 Study, in which was compared the effects
of using monosialotetrahexosylganglioside (GM1) vs. placebo in patients affected by cervical and
thoracic SCI (Geisler FH et al., 1991): the study showed the effectiveness of GM1 administration in
improving the recovery of lower extremities, probably due to a higher preservation of the axons in
the white-matter tracts passing through the injury site.
In a more complete trial, the Sygen Multi-center Acute Spinal Cord Injury study, the use of GM1
was compared to MPSS, resulting in a higher recovery over the first 3 months from the injury
(Geisler FH et al., 2001).
Thyrotropin-releasing hormone
Thyrotropin-releasing hormone (TRH) is a tripeptide produced by hypothalamus with endocrine
activity towards the pituitary gland. Besides its well known biochemical effects over endocrine
regulation  of  thyroid  hormones,  TRH  has  demonstrated  a  neuroprotective  role,  especially  in
animal  models  of  SCI  (Pitts  LH  et  al.,  1995;  Faden  A  et  al.,  2005),  via limitation  of  multiple
secondary injury factors, including reduced blood flow, inflammation mediators such as peptidyl
leukotrienes (Feuerstein G et al. 1983) and platelet-activating factor (Feuerstein G et al. 1984),
metabolic changes, deregulation of ionic homeostasis (Na+, K+, Ca2+, Mg2+) (Faden AI et al., 1990)
and blockade of opioids receptors (Faden AI et al., 1988).
Despite the strongly positive results deriving from animal studies, only a small clinical trial was
undertaken to assess the safety and the potential efficacy on a limited cohort of 20 patients (Pitts
LH  et  al.,  1995). Compared  to  placebo,  TRH  was  able  to  improve  neurological  and  sensory
functions in patients with an incomplete SCI after 4 months, while no differences were found in
patients  with  complete  SCI.  However,  due  to  the  limited  number  of  patients  and  the  high
fluctuations  found in  scores of  the control  group,  the results  should be considered promising
rather than definitive.
Glutamate receptors antagonists
One of the events occurring after the trauma is the massive glutamate release, due to the necrosis
of damaged neurons and to the deregulation of ions balance (especially Na+ and Ca2+) leading to a
release of the synaptic vesicles from the excitatory pathways, resulting in cells death. Moreover,
the  Ca2+ influx  causes  the  activation  of  cytoplasmic  proteases,  increasing  the  overall  nerve
damage.
To counteract these effects it might be useful the blockade of glutamatergic synaptic transmission,
although  some  concerns  might  arise  considering  that  glutamate  is  a  key  neurotransmitter
possessing  important  physiological  functions:  any  blockade  of  glutamatergic  pathway  may
potentially result in unwanted psychomimetic side effects. Furthermore, the therapeutic potential
of GluR antagonists has not yet been investigated for a clinical use in humans, due to the adverse
effects associated with the large doses eventually required (Baptiste  DC and Fehlings MG, 2006).
The feasibility and the effectiveness of ionotropic GluR  (AMPA and NMDA) antagonists use were
tested in preclinical studies (Wrathall JR et al., 1997; Gaviria M et al., 2000), in which was showed
an attenuated neurotoxicity  in  rodents  with almost  no side effects.  Regarding clinical  trials,  a
phase  III  study  was  completed  in  France  in  which  the  use  of  gacyclidine,  a  powerful  non-
competitive  NMDA  receptor  antagonist,  provided  early  benefits  at  1  month  from  the  injury,
although not maintained after 1 year  (Lepeintre JF et al., 2004). Metabotropic GluR antagonists
administration  showed  an  overall  positive  effects,  albeit  by  different  mechanisms:  while  1-
aminoindan-1,5-dicarboxylic  acid  (AIDA)  and  (1)-2-methyl-4-carboxyphenylglycine  (LY  367385)
were able to reduce mechanical  allodynia and to improve locomotor function (Mills CD et al.,
2002),  the  selective  mGluR5  blockade  by  using  2-methy-6-(phenylethynyl)-pyridine  (MPEP)
resulted in no effects on allodynia or locomotor behaviour, but elicited a significant sparring of
gray matter while reducing thermal hyperalgesia (Mills CD et al., 2002). Thus, the effects exerted
by mGluRs suggest differences in the pathological roles of these receptors during progression of
the injury, differences that might be selectively targeted for limiting the excitotoxic damage.
Ions channels blockers
To reduce the toxic  effects  of  the ions  unbalance  following  the spinal  injury,  the use of  ions
channels blocker might exert beneficial effects on the damaged spinal cord. The depolarization of
plasma membranes lead to a direct Ca2+ influx, or as a consequence of Na+ massive entrance, that
causes a reverse functioning of Na+/Ca2+ pumps (that normally allow Na+ to enter while Ca2+ is
pumped out of the cells).
As a consequence, there is the activation of calpains and others proteolytic enzymes leading to
further cells death, amplifying the primary damage.
Nimodipine is a Ca2+ channel blocker originally used for treating hypertension and vasospasm, it
showed a benefical effect in a rat and baboons model of SCI (Winkler T et al., 2003; Pointillart V et
al., 1993), due to improvements of the axonal function in motor and somatosensory tracts of the
cord.
In 1996 was held in France a small clinical trial in which the use of nimodipine was compared to
methylprednisolone, both versus no medical treatment: after 1 year of follow-up, though there
were some neurological ameliorations , no benefits were found in using nimodipine or MPSS vs
controls (Pointillart V et al., 2000 ).
Regarding the use of sodium channel blockers, preclinical studies on rodents showed therapeutical
effects exerted by tetrodotoxin (TTX) or amiloride (Rosenberg LJ et al., 1999;Jung GY et al., 2013;
Durham-Lee JC et al., 2011). Tetrodotoxin, after focal administration  by microinjections, was able
to reduce functional deficits by sparing of large-diameter axons, to decrease the axonopathies by
reducing the development of extensive periaxonal spaces (Rosenberg LJ et al., 1999). Furthermore,
TTX reduced early microglial activation, exerting a beneficial effect on the lesioned tissue (Jung GY
et al., 2013). 
Amiloride, a diuretic used as antihypertensive drug, was shown to have neuroprotective effects in
neurological diseases (e.g. brain damage and brain ischemia). In 2011 its therapeutic potential was
tested in a rat model of SCI:  following a daily administration from 24 h to 35 days after the lesion,
the animals exhibited a significant improvement in their motor behavior. The authors related the
beneficial effects of amiloride to a higher sparing of oligodendrocytes in treated rats compared to
controls (Durham-Lee JC et al.,  2011).
Riluzole, a benzothiazole anticonvulsant Na+ channel blocker, is known to exert a neuroprotective
role, promoting functional recovery following SCI in rodents (Schwartz G and Fehlings MG, 2001).
It was shown that riluzole is able to significantly reduce tissue loss in the area surrounding the
lesion epicenter, macrophages infiltration and astrogliosis at lesion site. These effects reflected in
a reduced apoptosis of nerve cells, concurring in sparing a higher amount of tissue (Wu Y et al.,
2014). Furthermore, riluzole exerts beneficial effects also by reducing mechanical allodynia and
thermal  hyperalgesia,  as resulted in a rat  model of cervical  radiculopathy (Nicholson KJ  et  al.,
2014). In 2010 the North American Clinical Trials Network (NACTN) undertook a phase I clinical
trial to investigate the safety and pharmacokinetics of riluzole, and to gain pilot data on its use on
patients affected by cervical  and thoracic spinal  cord injury. The authors observed no adverse
effects, as well a significantly higher motor score for riluzole-treated patients (Grossman RG et al.,
2014).
Minocycline
Minocycline  is  a  semi-synthetic  derivative  of  tetracycline  able  to  exert  an  anti-inflammatory
activity as well as its classical antibiotic function. Its anti-inflammatory properties in SCI are due to
a sum of actions, as a diminished lipid peroxidation (Sonmez E et al., 2013), a normalization of
NMDA receptor activity with a reduced excitotoxicity (Nie H et al., 2010), a reduction in microglia
activation and in Repulsive Guidance Molecule A (RGMa) expression (Kitayama M et al., 2011) and
finally to an analgesic effect (Rojewska E et al 2014). In a rat model of SCI, minocycline showed a
higher therapeutic effect compared to  methylprednisolone (Wells  JE et  al.,  2003),  thanks to a
diminished oligodendrocytes apoptosis, a lower microglial activation thus reducing the lesion and
improving the neurologic and motor function.
In a clinical trial undertaken to assess dose optimization and treatment safety, patients treated
with minocycline had an overall  greater motor  recovery compared to placebo (Casha S et  al.,
2012).  While patients with a thoracic  SCI  did not show any benefit  from drug administration,
patients with cervical SCI showed a great improvements compared to controls, as well as a higher
dose exerted the greater effects. The authors ascribe these results to a higher sensitivity of the
ASIA  motor  exam  for  cervical  injuries.  The  sensory  function  was  also  most  preserved  in
minocycline treated group.
Erythropoietin
Besides its well-known effects on erythropoiesis, erythropoietin (EPO) was shown to possess a role
also in neural  development and neuroprotection (Alnaeeli  M et al.,  2012; Erbayraktar  S et al.,
2003): in animals models of neurodegenerative diseases, like Parkinson and Alzheimer, EPO was
able to improve the neurological functions (Jia Y et al., 2014; Maurice T et al 2013) by reducing
apoptosis and lipid peroxidation.
EPO was able to reduce ischemic/reperfusion and traumatic brain damage, improving recovery of
sensorimotor function (Xiong Y et al., 2008; Cruz Navarro J et al., 2014; Wu SK et al., 2014). Similar
effects were proven in animal models of spinal cord injury, in which EPO administration, or its
vector-mediated overexpression, induced significant improvements in motor function, due to a
marked attenuation of secondary inflammation,  thus minimizing the injury size and enhancing
tissue sparing, preserving large-caliber axons and with an improvement of both ascending and
descending nerve pathways transmission (Gorio A et al., 2002; Wang S et al., 2012; Cerri G et al.,
2012).
The safety for a use of EPO in humans was assessed in a clinical trial concluded in 2002, where
erythropoietin was administered in patients affected by stroke: the study showed the beneficial
effects  of  EPO  in  improving  the  outcome,  acting  over  the  later  events  (like  apoptosis  or
inflammation) following the brain injury (Ehrenreich H et al., 2002).
However, several concerns are arisen by a chronic use of EPO, especially for its physiologic role on
erythropoiesis, as the damage might be increased by high hematocrit levels (Wiessner C et al.,
2001); for this reason researchers are focusing on developing EPO derivatives (e.g. asialo-EPO and
carbamil-EPO) lacking activity on erythropoiesis (Erbayraktar S et al., 2003; Leist M et al., 2004).
Cell therapy
To date,  the classical  pharmacological  treatments  are  designed to counteract  the detrimental
effects  of  inflammation  and  the  other  processes  leading  to  secondary  damage.  However,
enhancing  the  regeneration  of  the  lesioned  tissue  could  represent  an  improvement  in  the
treatment of the pathology: in this scenario the cellular therapy could be regarded as a powerful
tool, as it could grant the possibility to regenerate the lost fibers thanks to the integration of the
transplanted cells into the circuitry of the spinal cord.
Embryonic stem cells
Embryonic stem cells (ES) are pluripotent cells derived from the inner cell mass of the blastocyst,
characterized by the ability to proliferate and differentiate into all the cellular lineages deriving
from the 3 germ layers. Potentially, ES are a powerful tool for cell therapy towards many diseases,
due to their plasticity and differentiation abilities (Andres RH et al., 2008; Abdelli LS et al., 2012).
ES  transplantation  was  shown  to  exert  therapeutic  effects  towards  many  neurodegenerative
diseases, where the positive effects were often mediated by production and release of trophic and
anti-inflammatory factors (Kerr CL et al., 2010; Bottai D et al., 2010; Riess P et al., 2007). However,
the use of embryonic stem cells rises both technical, due to the ability to form tumors (Riess P et
al., 2007) once transplanted, and ethical concerns, that limits clinical use (Barker RA et al., 2013).
In 2006 the Nobel prize Shinya Yamanaka developed a technique that allows to reprogram fully-
differentiated  somatic  cells  into  pluripotent  cells,  named  iPS  (induced  Pluripotent  Stem  cells)
(Takahashi K and Yamanaka S, 2006),  allowing to overcome many issues bound to ES use in cell
therapy and transplantation. One of the most important issue linked to the use of stem cells in
vivo concerns the histo-compatibility between donor and host, how it is dramatically seen for the
graft vs. host disease (Blood. 2014Markey KA). Using pluripotent syngeneic cells should reduce the
issue (Guha P et al., 2013; Araki R et al., 2013), although it is still not clear if iPS or iPS-derived cells
are immunogenic (Zhao T et al 2011; Cao J et al., 2014). 
Neural stem cells
Neural stem cells (NSC) are a specific subpopulations of cells derived from the subgranular zone
(SGZ) of hippocampal dentate gyrus, the subventricular zone (SVZ) of the lateral ventricles, the
spinal cord or, in embrionic stage, from the neuroepithelium. During fetal life, their primary role is
the  formation  of  the  developing  nervous  system,  while  in  the  adult  their  role  become more
complex: beside a classic neurogenic activity (in rodents neural stem cells from the SVZ migrates
through the rostral migratory stream towards  the olfactory bulb, where they fully differentiate
into inter-neurons) (Lazarini F et al.,  2014), in the last years NSC were found to be involved in
immune modulation and immune surveillance (Mohammad MG et al., 2014; Butti E et al., 2014). 
Due  to  their  origin,  NSC  are  the  best  candidate  for  transplantation  in  animal  models  of
neurodegenerative diseases, where they showed therapeutic efficacy in improving the outcome
(Zhang W et al., 2014; Butti E et al., 2012; Kang X et al., 2014),  directly integrating in the tissue
(Brilli E et al., 2013) or more often by releasing neurotrophic/immune-modulatory factors (De Feo
D et al., 2012; Su P et al., 2014).
In spinal cord injury models, transplanted NSC were able to induce a higher motor recovery, by
preserving the lesioned tissue and, in general, by reducing the secondary damage (Cusimano M et
al., 2012; Bottai D et al., 2008) rather than integrating into the spinal cord. Despite the promising
results, at least in animal models, the eventual use of NSC in human is affected by technical and
ethical  issues,  due  to  the  cells  source  (human  foetuses)  and  its  limited  availability  (need  of
multiple foetuses to get enough cells for transplantation in humans) (Barker RA et al., 2013). In
order to obtain a high-proliferating cell population that could provide the great number of cells
needed  for  human  transplantation,  some  authors  performed  transplant  of  iPS-derived  neural
precursor  in  animal  models  of  neurodegenerative  diseases:  these  cells  behaved  similarly  to
classical NSC, improving the behavioral outcome (Romanyuk N et al., 2014;Tucker BA et al 2011;
Wang S et al., 2013; Sareen D et al., 2014), and thus providing a useful tool for therapy.
Amniotic fluid cells
Amniotic fluid cells (AF) appears in the amniotic fluid starting from the 12° gestational week, and
derive  both  from  extra-embryonic  structures  (i.e.,  placenta  and  fetal  membranes)  and  from
embryonic  and fetal  tissues (Gosden CM, 1983).  A morphological  classification divides AF into
three  main  groups:  epithelioid,  amniotic  fluid,  and  fibroblastic  type,  though  this  classification
reflect different characteristics regarding growth rate and markers expression (Cremer M et al.,
1981).  The use of amniotic fluid-derived cells was suggested for the first time in 2001 (Kaviani A et
al.,2001): the cells used had a mesenchymal profile and were able to colonize a polimeric scaffold
that might be eventually used in tissue engeneering. In 2006, AF cells were use in a animal model
of spinal cord injury, where they succeeded in improving repair of the damaged tissue, ensuring a
higher recovery (Wu ZY et al.,2006). Besides the  aforementioned classification, in 2000s deeper
studies  revealed  the  presence  of  two  main  population  of  AF,  according  to  phenotipic
characteristics: amniotic fluid mesenchymal stem cells and amniotic fluid stem cells (In't Anker et
al., 2003; Prusa AR et al., 2003). While the first population expresses typical mesenchymal markers
(e.g. CD 73,90,105) and is able to differentiate into cells belonging to the adipogenic, chondrogenic
and adipogenic lineages, the second is characterized by the expression of Oct4, SSEA-4 and c-Kit,
classical  pluripotency  markers,  and  by  the  capacity  to  differentiate  into  cells  lineages
representative of all three embryonic germ layers  (Kim J et al., 2007; De Coppi P et al., 2007;
Moschidou D. Mol Ther. 2012).
It was demonstrated that CD117+  AF cells forms embryoid bodies (Oncogene. 2010 Valli A) and,
after a minimal manipulation with Valproic acid they acquire embryonic characteristics, including
the expression of the “Yamanaka factors” (OCT4, NANOG, SOX2 and c-MYC, KFL4), the formation
of beating embryoid bodies in vitro and in vivo formation of teratomas (Moschidou D. Mol Ther.
2012 ).
Given this useful properties, recent studies using these cells were undertaken for diseases like
myocardial infarction (Chiavegato A J Mol Cell Cardiol. 2007; Bollini S Stem Cell Rev. 2011), neuro-
muscular diseases (Piccoli M Stem Cells. 2012), acute tubular necrosis (Perin L. PLoS One. 2010),
lung damage (Buckley S Am J Respir Cell Mol Biol. 2011).
Besides these innate “pluripotency” properties, AF cells raise almost no ethical concerns, as they
derive from a tissue otherwise discarded, especially for third trimester derived AF cells. For these
reasons, AF could represent a useful and powerful tool for cell therapy.
METHODS
Cell culture
Cells belonging to cultures 1.1, 3.5, 3.6, 7.30 and 9.1 were grown in AFCS medium (containing
DMEM, 10% fetal bovine serum [FBS], bFGF (fibroblast growth factor) 5 ng/ml, glutamin 2mM,
penicillin/streptomicin 100 U/ml) in an incubator at 37° C, 5% CO2 and O2. Once confluent (every 4-
5 days), the cells were splitted using a tripsin-like solution (TrypLE Express, Invitrogen), counted
and seeded at a density of 10.000 cells/cm2. 
When necessary the cells were frozen by means of liquid nitrogen using a solution containing
DMEM, 5% FBS and 10% dimethylsulfoxide (DMSO). 
To  make  easier  tracking  the  cells  once  transplanted,  the  ones  used  in  vivo were  marked
immediately before their administration to the mice using Qtracker Cell Labelling Kit (Invitrogen), a
fluorescent dye internalized by passive endocytosis. First it was prepared the labelling solution by
adding 1 µl of reagent A with reagent B (both provided with the kit), incubating for 5’ and then
adding this  solution to 200 µl  of  culture medium.  The cells  were incubated with the labelling
solution for 45’ at  37° C, washed twice with DMEM and finally suspended in PBS (Phosphate-
Buffered Saline) 0,01M at a concentration of 104 cells/µl, ready for the transplant. 
Spinal cord injury, transplant and animal care
Male, three months old CD1 mice were injured at T8 level by using an impactor (Infinite Horizon
Device), in order to produce a contusive damage.
The animals were anesthetized using a 4% chloral hydrate in PBS solution, the skin cut and the
dorsal muscles exposed. These were cut and moved to exhibit the spine. After the laminectomy of
the vertebra, the spinal cord was exposed and mildly injured with a force of 50 kDyne on a vertical
displacement range between 300 and 600 µm. Next the muscles and skin were sutured. After
surgery and for the following week the mice received 2 ml of saline, painkillers (buprenorphine
0,03 mg/Kg) and antibiotics (Pen/Strep 100 U/ml  100 mg/ml) daily. 
Immunosuppression  started  the  day  before  cells  transplantation:  the  mice  received  an
intraperitoneal injection  with Cyclosporin A (Sigma-Aldrich) 50 mg/Kg for one week, 25 mg/Kg for
3 days and 10 mg/Kg for 18 days.  Cells belonging to cultures 1.1, 3.5, 3.6, 7.30 and 9.1 were
transplanted 7 days after injury by means of 2 i.v. injections  containing 500.000 cells each, while
controls animals received the vehicle (PBS). The expression of mice's bladder was performed daily
until bladder reflex recovered. 
Behavioural analysis
In  order  to  assess  the  motor  recovery  induced  by  the  transplant,  the  motor  behaviour  was
analyzed for 4 minutes in a open field by using the Basso Mouse Scale (Basso et al 2005), which
allows to couple the motor performance to a numeric value. The analysis started the day following
the lesion, the mice analyzed every 3 day until the 35  th   day after the lesion (28 days from the
transplantation).
SCORE ANIMAL MOVEMENT
0 No ankle movement
1 Slight ankle movement (angle ≤ 90°)
2 Extensive ankle movement
 (angle ≥ 90°)
3 Plantar placing of the paw with or without weight support or occasional, frequent
or consistent dorsal stepping but no plantar stepping
4 Occasional plantar stepping
 (number of plantar steps ≤ 50% of the overall movement time)
5 Frequent  (number  of  plantar  steps  ≥  50%  of  the  overall  movement  time)  or
consistent (less than 5 missed steps in the overall  movement time) plantar step
with  no  coordination  or  frequent/consistent  plantar  stepping  with  some
coordination) and paws rotated at inizial contact and lift off
6 Frequent or consistentplantar stepping with some coordination and paws parallel
at  initial  contact  or  consistent  plantar  stepping  mostly  coordinated  and  paws
rotated at initial contact and lift off 
7 Frequent o consistent plantar stepping mostly coordinated, paws parallel at initial
contact  and  rotated  at  lift  off  or  frequent/consistent  plantar  stepping,  mostly
coordinated, parallel paws at initial contact and lift off with severe trunk instability 
8 Frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial
contact  and  lift  off  andmildt  trunk  instability  or  frequent/consistent  plantar
stepping, mostly coordinated, paws parallel at initial contact and lift off, normal
trunk stability, tail up and down 
9 Frequent or consistent plantar stepping, mostly coordinated, paws parallel at initial
contact and lift off, normal trunk stability, tail always up
Table 1  Basso Mouse Scale summary scheme
Harvest of spinal cord samples and histochemical analysis
Some animals were sacrificed at 2, 7 and 28 days after transplantation in order to collect the spinal
cord.  Following  a  lethal  anesthesia  with  4%  chloral  hydrate,  the  mice  were  perfused  with  a
solution of PBS with 4% formaldehyde, the spines collected, kept overnight in 4% formaldehyde
and washed 3 times with PBS. Afterwards the tissues were kept in  15% sucrose for 3 h, 30%
sucrose  overnight,  and  finally  included  in  OCT  (Optimal  Cutting  Temperature  compound  Bio-
Optica) and maintained at -80° C. The samples were cut, mounted on coverglasses and kept at -20°
C until the analysis. 
For the immunostaining the slides were rinsed with PBS, blocked with a solution of 2% normal
goat serum (NGS), 1% bovine serum albumin (BSA) and Triton 0,1% in PBS and then incubated
overnight with primary antibody at 4° C. Later, the sections were washed 3 times with PBS and
incubated 45’ with secondary antibody (Alexa 555/546 α-mouse/rabbit 1:1000; Alexa 488 α-rabbit,
1:1000)  at  room  temperature.  Finally,  after  labelling  the  nuclei  with  DAPI,  a  coverslip  was
mounted with FluorSave Reagent (Calbiochem). 
Antigen Antibody dilution Brand
MOMA-2   (Anti  Monocyte-
Macrophage Antibody-2)
1:25 Chemicon
GFAP  (Glial  Fibrillary  Acidic
Protein)
1:500 Covance
Β-tubulin III 1:200 Covance
NG-2 (Neural/Glial Antigen-2) 1:100 R&D
CD31  (Platelet Endothelial Cell
Adhesion Molecule-1)
1:70 Santa Cruz
Nestin 1:100 R&D
Table 2 List of antibody used for immunofluorescence
The myelin preservation was assessed by use of FluoroMyelin (Life Technologies), a fluorescent
dye, following the producer’s instructions: briefly, the spine section spanning the lesion site for 5
mm  were  rinsed  with  PBS,  incubated  with  the  dye  for  20’  (1:300),  washed  again  with  PBS,
counterstained with DAPI and finally mounted with FluorSave.
The evaluation was carried on comparing the ventral horns white matter of transplanted mice vs.
controls; in this area it is present the reticular spinal pathway, involved in the regulation of hind
limb movement in mice (Vitellaro Zuccarello 2007). 
The angiogenesis assessment at 800 and 1600 µm from lesion epicenter was made as a double-
staining  with  antibodies  against  CD31  and  lectin  (Texas  Red  Lectin,  Vector  Laboratories),  a
hemoagglutinin able to bind specifically endothelial glicoproteins.
Lectin staining was performed accordingly to producer’s protocol: first, the samples were rinsed
with PBS, then incubated with lectin (diluition 1:50) for 2h, wash 3 times with PBS, counterstained
with DAPI and mounted as described before.
Plasma and tissues harvesting
The animals were sacrificed at 2 and 7 days from transplant using a lethal injection of 4% chloral
hydrate. After a laminectomy of the vertebrae between T5 and T12, the spinal cord was collected,
placed in Tri Reagent (Sigma) and kept at -80° C. The lungs were divided as follows: one was kept
overnight in 4% paraformaldehyde, washed with PBS, treated with 15% sucrose for 3h and 30%
o/n, then kept at -80° C in OCT with 30 % sucrose; the other part was put in TRI Reagent and
stored at -80° C. The blood was harvested in tubes containing a solution of 3,8% w/v of citric acid
in water and centrifuged at 1800 g for 10’. The plasma was then collected and saved at -80° C until
analysis. 
The protein quantification was performed using Lowry-Ciocalteau method.
First Lowry’s solution was prepared, using solution A (NaOH 0,4% e Na2CO3 2% in H2O) to dilute
1:50 solution B (sodium tartrate 1% e CuSO4 0,5%). Two µl of plasma were added to water, to a
final volume of 200 µl , then 1 ml of Lowry’s solution was added, incubating for 15’. After that 100
µl of Folin’s reagent were added and the adsorbance  red.  
The standard curve was made using a solution of BSA in water, with a concentration from 0 to 35
µg. 
RNA extraction, retrotrascription and analysis 
The samples from spinal cord and lung collected 2, 7 and 28 days after transplantation were put
into TriReagent and the RNA extracted following manufacturer’s protocol: after adding 0,2 ml of
Chloroform for each ml of TriReagent, the samples were shaken vigorously, incubated 10’ at room
temperature and centrifuged 15’ at 4° C at 12000 g. The aqueous phase was transferred to a new
tube containing 0,5 ml of isopropanol, mixed and incubated 10’ at RT, then centrifuged at 12000 g
for 10’ at 4° C. The supernatant was discarded, the pellet containing the RNA was washed with
75% ethanol and then solubilized into 50 µl of RNase-free water. Afterwards the RNA was treated
with a Dnase,  to remove any contamination with genomic DNA: 10X Dnase reaction mix was
diluted tenfold with the RNA, than the reaction mix was incubated for 1h at 37° C. After the RNA
was purified with PCI solution (Phenol,Chloroform, Isoamilic acid), precipitate with 75% Ethanol
and resuspended in water; lately, it was quantified by NanoDrop (NanoDrop 2000c, Thermo Fisher
Scientific Inc.). Afterwards 0,5 µg of RNA were retrotranscribed using the iScript cDNA Synthesis
Kit (BioRad), following  manufacturer's protocol; the reaction mix was then incubated  5' at 25° C,
then 30 minutes at 42° C and lastly  5' at 85° C, in order to deactivate the retrotrascriptase. The
cDNA was then brought to a final volume of 50 µl with H2O.
The real-time PCR analysis was performed using iQ SYBR Green Supermix (BioRad), the primers
concentration was 5 µM (see table 3 for primers sequences), while the choice of the housekeeping
genes and the final analysis was made using qBase (Biogazelle) software.
Gene Forward Reverse Product lenght
Mm GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 86
Mm HPRT-1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 94
Mm Ciclo GCGTCTCCTTCGAGCTGTT AAAGTCACCACCCTGGCA 146
Mm β-µTub ATTCACCCCCACTGAGACTG TGCTATTTCTTTCTGCGTGC 182
Mm BDNF CATTACCTTCCTGCATCTGTTG
G
CGTGGACGTTTACTTCTTTCATG
G
158
Mm CNTF ACATCAGTCTCCCGGTGGCAT
TAG
TTCTCCGTGGCTTTGGGGTTTC 151
Mm IL6 GACAACCACGGCCTTCCCTAC CGTTGTTCATACAATCAGAATT
GCC
169
Mm LIF AACGTGGAAAAGCTATGTGCG GCGACCATCCGATACAGCTC 101
Mm HIF TCAGTGCACAGAGCCTCCT GCGGAGAAAGAGACAAGTCC 209
Mm NGF TGGGCCCAATAAAGGTTTTGC
C
TGGGCTTCAGGGACAGAGTCT
CC
165
Mm NT3 ACGTCCCTGGAAATAGTCACA
CG
TTGGATGCCACGGAGATAAGC 109
Mm TNFα TCTATGGCCCAGACCCTCACAC CAGCCACTCCAGCTGCTCCTC 100
Mm VEGF ACACGGTGGTGGAAGAAGAG CAAGTCTCCTGGGGACAGAA 145
Mm PGF CACTTGCTTCTTACAGGTCC CACCTCATCAGGGTATTCAT 174
Mm IL1β CATGGAATCCGTGTCTTCCT GAGCTGTCTGCTCATTCACG 100
HGF TTGTCCCACATGGAACATGTA
AG
CACTGACCCAAACATCCGAGTT 149
Hs IL1β TTACAGTGGCAATGAGGATGA TGTAGTGGTGGTCGGAGATT 131
Table 3 Primer used for mRNA analysis
Western blot of plasma proteins
Ten µg of proteins derived from plasma samples collected 2, 7 and 28 days after trasplantation
were analyzed by Western Blot. After treating the proteins with 5% β-mercaptoethanol at 100 °C,
in order to disaggregate protein complexes and to denaturate quaternary structures, they were
run  on  a  10%  polyacrilamide  gel  at  120  V.  The  transfer  was  performed  on  a  nitrocellulose
membrane for 1h at 100 V. The membrane was then coloured with Ponceau Red (Sigma) to assess
the transfer, washed with T-TBS (Tris Buffer Saline Solution containing 0.05% Tween-20), treated
2.5h with a blocking solution (5% dry milk in T-TBS) and incubated at 4° C o/n with the primary
antibody α-HGF (dilution 1:200, Santa Cruz Biotechnology). Afterwards the membrane was rinsed
twice with T-TBS and incubated 1h with the secondary HRP-coniugated antibody (1:5000), washed
again 3 times with T-TBS, once with TBS and finally it was added the substrate (SuperSignal West
Femto, Pierce). The results were analyzed with Kodak MJ software. 
Immunohistochemical analysis of the lungs
Lung  samples  were  collected  2  and  7  days  after  transplantation,  fixed  overnight  in  4%
paraformaldehyde, washed with PBS, treated with 15% sucrose for 3h ad 30% o/n, included in OCT
and cut with a cryostat. The slides were rinsed twice with PBS and then blocked with a blocking
solution (2% NGS, 1% BSA and Triton 0,1% in PBS) and then incubated overnight with primary
antibody α-HGF (1:200, Santa Cruz Biotechnology) at 4° C. Later, the sections were washed 3 times
with  PBS  and  incubated  45’  with  secondary  antibody  (Alexa  488  α-rabbit,  1:1000)  at  room
temperature. Finally, after labelling the nuclei with DAPI, a coverslip was mounted with FluorSave
Reagent (Calbiochem).
Proinflammatory stimulations of cells
Cells belonging to culture 7.30 and 9.1 were seeded at a density of 15000 cells/cm2 in a 48 wells
plate. The next day the medium was changed with AFCS medium containing IL-1β (0,1 ng/ml) and
LPS (200 ng/ml), the cells were kept in this medium for different times (2, 4, 8, 16 and 24 h).
Negative controls were kept in the same medium not added with the chemicals. At the end the
cells were fixed with 4% paraformaldehyde for 10’, rinsed with PBS and kept at 4° C until analysis.
The cells were washed twice with PBS, permeabilized with 0.1% Triton X-100 in PBS and then
incubated  o/n  with  primary  antibody  α-HGF  (1:  300,  Santa  Cruz  Biotechnology)  diluted  in  a
solution of NGS 10% in PBS. After this,  the cells were washed twice with PBS, incubated with
secondary antibody (1:1000),  counterstained with dapi,  mounted with FluorSave and stored at
-20°C.
RESULTS
Motor behavior analysis
According to our contusion model of spinal cord injury, mice transplanted with the vehicle (PBS)
have a physiological recovery from the injury, allowing them to reach a score of about 3 in the
BMS, corresponding to the capacity of moving the hind limbs, or using them to sustain the body
weight. The mice transplanted with the cells reached different scores, depending on the cell line
they received during the transplantation: some of the cell lines (3.5, 3.6, 7.30) caused a significant
increase in the motor performance, while other (1.1, 9.1) had no differences respect to controls
(Fig. 1A). It was decided to split the cells into a therapeutic group (T-AFs) and a non-therapeutic
group (NT-AFs), according to the effects they have on the animals (Fig. 1B): the average score of
mice treated with T-AFs is 4.83 ± 0.23 (n = 33) versus PBS 3.80 ± 0.22 (n = 33, p< 0.01), versus NT-
AFs 3.36 ± 0.210 (n = 7, p<0.01). These results correspond to the possibility for the mice to use
actively the hind limbs to walk, while controls or NT-AFs treated mice can barely sustain their body
weight. 
Figure 1: Effect of PBS and AFCs treatments on motor activity after SCI. motor recovery was evaluated over one month
period (time= days), and the assessment was based upon the 9-point BMS scale. Values represent means±SEM. A:
Comparison of motor recovery between cell-treated and PBS-treated animals.  PBS treated mice (n = 33); ▼ ▪ #3.5 AFs
treated animals (n = 16); ◊ #3.6 AFs-treated animals (n = 8); □ #7.30 AFs-treated animals (n = 15);  ○ #9.1 AFs-treated
animals (n = 9); ● #1.1 AFs-treated animals (n = 6).   B: Comparison of motor recovery after formation of the groups:
▪T-AFs-treated mice (n = 39); ● NT-AFs-treated mice (n = 15);   PBS-treated mice (n = 33). Significance symbols: ***;▼
°°°: p b 0.001; **, °°: p b 0.01; *, °: p b 0.05. ***, ** and * T-AFCs-treated mice versus PBS-treated mice; °°°, °° and ° T-
AFCs-treated mice versus NT-AFCs-treated mice. BMS: Basso Mouse Scale.
Surprisingly,  the  T-AFs  cells  (cultures  #3.5,  #3.6,  #7.30)  express  the  NG2  (Chondroitin  Sulfate
Proteoglycan)  marker,  while  the  NT-AFs  (cultures  #1.1,  #9.1)  do  not  (Fig.  2).  This  marker  is
normally associated to oligodendrocyte precursor cells, but it can be also found in endothelial
cells, and it might have a role in the therapeutic effects observed (Stallcup WB, Huang FJ 2008).
Figure 2: NG2 expression in four of the transplanted cultures: A #7.30, B #3.5, C #9.1, D # 1.1.
Histochemical analysis of spinal cord
In  order  to  link  the  motor  performance  to  eventual  differences  in  tissue  preservation,  we
performed a volumetric analysis of myelin content in a 5 mm region across the lesion site. The
areas analyzed were located in the ventral horns of the spinal cord, as in that regions are located
the descending portions of the reticulospinal tract, particularly important for coordination of the
rhythmic stepping movements and in eliciting locomotion (Ballermann M. and Fouad K. 2006). It
was decided to focus on this  particular  region as it  might be partially  spared in our  lesioning
paradigm, affecting the dorsal and central part of the spinal cord . As result, it was observed a
higher myelin content in mice transplanted with T-AFs respect to controls,  probably  due to a
better  preservation of  myelin itself  (Fig.  3):  the myelin content is indeed 70% higher in T-AFs
treated mice compared to PBS; no differences were found between PBS and NT-AFCs groups.
Figure 3:  Analysis of myelin. A: Myelin content in a 5mm region crossing the injury site, in a T-AFs (red) treated mouse
and in a PBS-treated control (black), B: FluoroMyelin staining at 1.2 mm rostrally to the lesion (a and b), in the lesion
epicenter (c and d) and 1.5 mm caudally to the lesion (e and f); a, c and e T-AFs treated animal, b, d and f PBS treated
animal), arrows indicate the ventral funicoli were the ventral reticular spinal tract is located. C: Statistical analysis of
the  changes  in myelin  levels  in  transplanted animals  compared to the control  PBS-treated animals.  These results
represent the difference in myelin levels in a cord region spanning the lesion site; the data were obtained as average of
the  outcome  of  different  cellular  treatments:  #3.5,  #3.6  and  #7.30  compared  to  the  vehicle  treatment.  Values
represent means ± SEM. Significance symbols: **: p < 0.01. Scale bar 100 μm. AU: arbitrary unit.
The number of cells found at lesion site is not high enough to sustain the integrative hypothesis,
although there are some phenotypical changes in the cells, especially for the expression of typical
neural marker such as GFAP and β-TUB III (Fig. 4A). We were able to find cell in which there was a
total loss of the expression of the markers (Fig. 4-1), other in which was lost β-TUB III (Fig. 4-2) or
GFAP (fig. 4-3) expression and finally cells which maintained the expression of both markers (Fig.
4-4).
Figure  4: Immunofluorescence staining of the spinal cord 1 mm rostrally to the lesion site. AFs labeled with Q-dot
(magenta) were transplanted in lesioned mice one week after contusion. Immunostaining for GFAP (green), β-tubulin
(red) nuclei (blue), and Q-dot staining (magenta). A: low magnification of the spinal cord ventral horn. Magnifications
1,  2,  3  and 4 indicated in  Figure  A by  rectangles.  Enlargements  also reported their  thickness  (xz,  yz)  in  order  to
highlight the cellular localization of the GFAP, β-tubulin, DAPI and Q-dot, Scale bar in A is 75 μm, in the enlargement 1
(representative for all the magnifications) scale bar is 25 μm.
Following the double staining with CD31 and lectin it was found a statistically significant increase
in volume of blood vessels in T-AFs treated mice compared to controls (Fig. 5) at 900 µm rostrally
the injury site, while no differences were detected at 1600 µm between the two groups. Figure 5-
A shows a lesioned not transplanted animal (PBS), while in fig. 5-B it is shown a lesioned and cell
transplanted animal (T-AFs). It is clear the co-localization of CD31 (green) and lectin (red) (shown
in the enlargements 1 and 2 respectively from panel A and B); some non-vessel staining is present
for  CD31 and most likely  represents  the staining of  platelets and some sub-populations  of  T-
lymphocytes.  In  5-C  is  shown the  quantification  of  total  vessels  volume in  transplanted  mice
compared to controls: the increase detected was almost the 70% higher in T-cells treated animals
vs. PBS.
Figure 5: Vascular compartment in the ventral horn 0.9 mm rostrally to the site of injury. A and B confocal
analysis of lectin (red) and CD31 (green) co-staining of 10 μm thick transverse section. A: PBS-injected mouse; B:
T-cells injected mouse; C: Statistical analysis  of the relative changes in lectin levels in transplanted animals
compared to the control animals. 1 and 2 enlargements respectively of panel A and B. Values represent means
± SEM. AU: arbitrary units. Scale bar 100 μm for A and B, scale bar 10 μm for enlargement 1 and 2. Significance
symbols: **: p < 0.01.
Regarding the inflammatory processes, we evaluated the presence of macrophages 400 µm from
the lesion epicenter: the number of macrophages counted in the area is significantly lower in
treated mice respect to controls (Fig. 6). In panel A is shown confocal analysis of a control mouse,
while B is relative to a staining of a T-cells transplanted mouse. The estimated MOMA-2 positive
cells number was 827 ± 244 (n = 3) in controls (Fig. 6C), and 300 ± 52 (n = 6) (p<0.05) in T-AFCs
treated animals, corresponding to a 63.7% decrease.
Figure 6: Staining for MOMA-2 (macrophages staining) 100 μm rostrally to the lesion epicenter, four weeks
after  the transplantation.  MOMA-2 in  red,  nuclei  in blue,  Q-dot in  green.  A) PBS-treated mouse;  B)  T-AFs-
treated mouse; 1, 2, 3, 4, 5 and 6 are enlargements (located by rectangles on the panels A and B) indicating the
distribution  of  the  MOMA-2  staining  and  the  presence  (enlargements  4,  5  and  6)  of  Q-dot  derived  from
phagocytosed  transplanted  cells.  C)  Relative  number  of  macrophages.  Values  represent  means  ±  SEM
.Significance symbols: *: p < 0.05. Scale bar 50 μm in B is representative also for panel A. Enlargements 1, 2, 3,
4, 5 and 6 scale bar 10 μm.
RNA extraction, retrotrascription and analysis 
The  mRNAs  deriving  from  spinal  cord  and  lung  samples  collected  2  and  7  days  after
transplantation  were  analyzed  by  means  of  Real-Time  PCR.  Regarding  the  spinal  cord,  no
differences were found concerning the expression of genes related to neurotrophic factors (e.g.
BDNF, NGF and others – data not shown),  while we found an increase in the expression of VEGF
(Vascular endothelial growth factor) at 2 and 7 days after the transplantation. The expression of
HIF-1α (Hypoxia Induced Factor 1α), a regulator of VEGF transcription, was increased at 2 days
while resulted decreased after 7 days from the transplantation. 
Mesenchymal  stem cells  are known to produce,  expecially  after  pro-inflammatory stimulation,
many cytokines with anti-inflammatory, trophic and pro-angiogenic properties (Soleymaninejadian
et al., 2012). Among these, we focused on HGF (Hepatocyte growth  factor), because of its anti-
inflammatory and angiogenic features. We then performed further Real-time PCR analysis, both in
spinal cord and in lungs, site of cells homing: while no differences were found in the spinal cord, in
the lungs HGF and IL-1β mRNA levels were significantly higher in mice that received T-AFs than
controls (PBS and NT-AFs).
Gene of
interest
sample Tissue analised Fold changes Time (days) from
transplant
Statistical
significance
MmVEGF Therapeutic/PBS Spinal Cord 2.4 2 P=0.029
MmVEGF Therapeutic/PBS Spinal Cord 2.4 7 P=0.029
MmHIF Therapeutic/PBS Spinal Cord 1.7 2 P=0.014
MmHIF Therapeutic/PBS Spinal Cord 0.15 7 P=0.029
HGF Therapeutic/PBS Spinal Cord none 2
HGF Therapeutic/PBS Spinal Cord none 7
MmIL-1β Therapeutic/Non
Therapeutic
Lung 2.28 2 P=0.036
HGF Therapeutic/Non
Therapeutic
Lung 1.4 2 P=0.047
Table 1: Summary of Real-Time PCR analysis and results in lungs and spinal cord
Immunohistochemical analysis of the lungs
In order to confirm HGF expression in lungs, we perform a staining for HGF in samples deriving
from  mice  transplanted  with  T-AFs,  NT-AFs  and  PBS  and  collected  2  and  7  days  after
transplantation (Fig.7). As a result, HGF protein levels are higher for both groups (T/NT-AFs mice)
after 2 days from transplant (20x for T-AFs and 12x for NT-AFs vs. PBS), while only the therapeutic
cells (represented here by culture 7.30) are able to sustain HGF production for a longer period (1
week) compared to culture 9.1 (representative of non-therapeutic cells) (8x T-AFs vs. PBS, 4x T-AFs
vs. NT-AFs) (Fig 7).  
Figure 7: HGF expressing cells in the lung two and seven days after transplantation. 
In panels A, F are shown the stainings for a  PBS-injected mouse; B, D and G: #9.1 (representative of NT-cells) and C, E,
and H: #7.30 (representative of T-cells); D and E represent magnifications of panels B and C respectively. In blue are
stained  the  nuclei,  in  green  HGF  positive  cells,  in  red  Q-dot  positive  cells.  A,  B,  C,  D  and  E:  two  days  after
transplantation. F, G and H: one week after transplantation. Lower graphs: quantification of the HGF expressing cells
two days (I) and seven days (J) after transplantation. Scale bar 50 μm in B is representative for all the pictures with the
exception of D where the bar scale is 30 μm (representative also for E). Significance symbols: *, °: p < 0.05, **: p < 0.01.
* groups #9.1 and 7.30 compared to the PBS group; ° comparison between group #9.1 and 7.30.
Western blot of plasma proteins
Given the previous results, we analyzed by western blot the HGF content in blood, as we were
assuming that it might reach the injury site via bloodstream, in order to elicit the response of the
damaged  tissue.  The  results  showed  a  significant  increase  of  HGF  plasma  level  in  mice
transplanted with T-AFs compared to NT-AFs and PBS 7 days after transplantation: mice receiving
cells 7.30 (chosen as representative of T-AFs group) have almost 2.5 times more HGF in their blood
than mice transplanted with cells 9.1 (chosen as representative of NT-AFs group) or controls (Fig.
8). No differences were found in plasma samples collected 2 days after cells transplant (data not
shown). 
Figure 8: HGF releasing in the blood circulation.
Western blot analysis of the HGF level in the circulating blood. A: western blot, in each lane was loaded the same
amount of protein as obtained by means of protein quantification. B: quantification of the panel A (n = 4 for each
sample), gray bar: PBS; dark gray bar: #9.1 and white bar: #7.30. Significance symbols: *°: p < 0.05.
In vitro production of HGF
Cells belonging to culture 7.30 and 9.1, representative of T-AFCs and NT-AFCs groups, have a basal
production of HGF. However, after a pro-inflammatory stimulation with IL-1  β and LPS the cells
raised their HGF production, with a peak at 16 h after the stimulation, although the 7.30 cells have
a higher increase, (4-fold vs. 1.7-fold) compared to 9.1 cells. Moreover, cells 9.1 are not able to
significantly increase the HGF production after stimulation with LPS (Fig. 9).
Figure 9: In vitro induction of HGF by means of inflammatory stimuli.
Interleukin (IL)-1β and LPS treatments of the cultures #7.30 (T-AFCs) and #9.1 (NT-AFCs) for 0, 2, 8, 16 and 24 h. In the
lower  panels  are  represented  the  summary  and  the  statistical  analysis  of  the  results  obtained  in  four  different
experiments. Scale bar 75 μm is representative for all the pictures. Significance symbols: *: p < 0.05.
DISCUSSION
Spinal cord injury (SCI) is a disabling degenerative disease that heavily impacts on patient's life
from a physical, psychological, and social point of view. In a 2011 study it was estimated SCI global
prevalence to be between 236 and 1,009 per million (Cripps RA et al., 2011), with a prevalence in
young man (Singh A et al., 2014). To date, the only treatment available is thought to target the
inflammatory processes sustaining the secondary damage: for this reason, finding new therapeutic
approaches able to elicit regeneration of damaged fibers is of primary importance, as it might
permit a complete recovery of the patient. In this regard, cell therapy might represent a useful
tool,  as the integration of transplanted cells might lead to a recover of tissue's  lost functions.
There  are  many  different  kind  of  cells  that  might  be  used  with  this  purpose  (for  example
embryonic  or  neural  stem  cells);  however  their  use  could  raise  some  technical  and  ethical
concerns, that might necessitate the use of novel cellular sources (Barker RA et al., 2013).
The  aim  of  the  present  study  was  therefore  to  assess  potential  therapeutic  activity  of  third
trimester amniotic fluid cells once transplanted in a mouse model of spinal cord injury. Despite the
expectations, only some of the transplanted culture were able to improve motor behaviour in the
animals: mice transplanted with therapeutic culture #3.5, #3.6 and #7.30 (T-cells) had an average
score of 4,83, corresponding to the ability to use the hind limbs to actively walk; while culture #1.1
and #9.1, resulted non-therapeutic (NT-cells), had an average score very similar to controls (3,36
vs. 3,80 respectively), allowing the mice to use the hind limbs only to sustain the body weight.
Further analysis  revealed that,  among the analyzed markers,  T-cells  were able to express the
surface marker NG2, while NT-cells were not. This fact is very important, as it might explain the
reason for cellular effectiveness: NG2, also called chondroitin sulphate proteoglican 4 (CSPG4) or
melanoma-associated chondroitin sulfate proteoglycan (MCSP) (Pluschke G et al., 1996), was first
identified on human melanoma cells  (Wilson BS et al., 1981), where it was able to increase the
tumorigenic and metastatic properties of the cells. In nerve tissue, NG2 is normally expressed by a
particular  subgroup  of  cells,  called  Oligodendrocyte  Precursor Cells  (OPC)  (Dawson MR et  al.,
2003), or Polydendrocytes (Nishiyama A et al., 2014), whose function is to produce remyelinating
cells (Young KM et al., 2013), even though  recent findings suggest a more complex role, especially
in  formation  of  non-myelinating  oligodendrocytes  and  in  pathogenesis  of  demyelinating
neurodegenerative diseases (Nishiyama A et al., 2009). In spinal cord injury models, NG2 positive
cells where thought to block endogenous regeneration, inhibiting assonal sprouting (Chen ZJ et al.,
2002;  Ughrin  YM  et  al.,  2006;  Tan  AM  et  al.,  2006).  Nevertheless,  recent  studies  suggest  a
beneficial effect of NG2 in regenerating damaged fibers (de Castro R et al., 2006;  Yang Z et al.,
2006), as well modulating neuronal networks (Sakry D et al., 2014) through synapses formation
with neurons and partecipation  into  hippocampal  long term potentiation  (Nishiyama A et  al.,
2009;  Ge  WP  et  al.,  2006).  NG2  is  also  present  on  the  surface  of  pericytes,  a  subgroup  of
perivascular cells able to make intimate connections with capillary endothelial cells (Birbrair A et
al.,  2014).  These cells  have a fundamental  role in  regeneration and formation of  new vessels
(Kabara  M et al.,  2014),  as  demonstrated in mouse models,  in which NG2 absence leaded to
aberrant  tumor  vascularization  (Huang  FJ  et  al.,  2010).  Furthermore,  NG2  positive  cells  are
important  for immune suirvellance, as pericytes are able to attract  leukocytes exiting through
venules and "instruct" them  through upregulation of adhesion molecules and chemoattractant
factors (Stark K et al., 2013). 
In the past years it was demostrated the ability for NG2 to bind growth factors, as FGF2 and PDGF-
AA, serving as co-receptor and thus enhancing their signalling (Goretzki L J Biol Chem. 1999). In a
corneal angiogenesis model, NG2 negative corneas showed a greatly reduced responsiveness to
FGF2 respect to wild type controls (Ozerdem U et al., 2004).
The therapeutic effects could not be exerted by AF cells integration into spine ciruitry,  as the
number of cells in the lesion site at 1 month from the transplant was not high enough to sustain
such hypothesis, even though some cells were induced to change their phenotype, altering GFAP
and β-TUBIII expressions. At the same time, T-cells were able to induce a greater myelin sparing in
a 5 mm perilesion region compared to NT-cells and PBS controls: the higher tissue preservation
might underlie the motor differences between the animal groups. To explain these results, very
similar to the ones previously obtained in our laboratory (Bottai D, et al 2008), it was performed a
Real-Time PCR analysis on neurotrophic genes expression, such as NGF, BDNF, LIF, NT-3, CNTF,
without finding any statistical difference between groups. 
AF cells express typical mesenchymal markers (Bottai D, et al 2012), moreover mesenchymal cells
are known to possess pro-angiogenic and immunomodulatory activity by producing and releasing
trophic and immunoactive molecules (Uccelli A, 2008; Pacini S, 2014) directly, or by stimulating
the production by endogenous tissues (Chen X et al., 2002). Thus, the positive action might be
explaind with a pro-angiogenic and immunomodulatory action of the cells: as hypothesized, AF
cells-induced angiogenesis is greater in T-cells treated mice compared to NT-cells or PBS treated
animals, effect obtained through a higher expression of HIF-1α (hypoxia induced factor 1 alpha)
and VEGF (vascular endothelial growth factor). This results were confirmed with a staining that
clearly showed a higher content  of  microvessels  in a perilesion site:  the increased number of
vessels may probably result in a more efficient debris removal by the blood flow, contributing in
sparing the tissue, as debris are known to be detrimental  for nerve regeneration (Kang H and
Lichtman JW, 2013).  Furthermore, the immune reaction is also lower in these animals,  as the
number of macrophages is significantly lower if compared to NT or PBS transplanted mice: this
may lead to a formation of a more pro-regenerative environment, resulting in the surviving of a
higher number of nerve cells. 
It is well known that MSC are almost entirely entrapped in the lungs when administered i.v. (Lee
RH et  al.,  2009),  though  it  is  not  clear  if  this  is  a  passive  process  or  MSC express  adhesion
molecules  that  determine  a  selective  homing:  it  was  shown  that  changes  in  materials  or
detachment procedures during in vitro culturing steps reduce lung entrapment, as the cells lose
affinity for the endothelium (Deak E et al.,  2010; Dreher L et al.,  2013; Kerkelä E et al.,  2013).
Similarly, the homing site for both T and NT-cells were the lungs, thus in order to find out the
molecular mechanism by which the cells exerted their therapeutic activity, it was performed a
qPCR analysis of gene expression.  Mesenchymal stem cells are known to produce HGF, a pro-
angiogenic, trophic and immunomodulatory polypeptide (Soleymaninejadian E et al., 2012), able
to supports the regeneration of organs like liver, kidneys, and lungs (Matsumoto K and Nakamura
T, 1996), especially after their "activation" through  several cytokines, like IL-1β, IL-6 and TNF-α
(Ren G et al., 2008; Trusolino L et al., 2010). HGF and its receptor (c-Met) are up-regulated after
injury  mainly  in  reactive  astrocytes  around  the  injured  region  (Shimamura  M  et  al.,  2007),
promoting functional recovery through immune suppression and induction of myelination. In  an
elegant study, Bai and colleagues clearly demontrated that, following MNS transplantation in an
multiple  sclerosis  mouse model,  the cells  elicited functional  recovery through production and
release of HGF (Bai L et al., 2012). After qPCR analysis of the lungs, HGF and IL-1β levels resulted
significantly higher in T-cells treated mice compared to NT-cells and PBS-treated controls, data
confirmed with immunohistochemical analysis of HGF production in the lungs. Furthermore, also
plasma HGF level was greater in these animals than in controls, significant of the ability for the
cells  to  recognise  stimuli  from  the  environment  and  to  react  by  changing  their  proteins
production.
Further in vitro studies showed a correlation between inflammatory state (induced by IL-1β and
LPS addition to culture media) and HGF production by T and NT-cells, with a significantly greater
synthesis by T-cells, with a peak at 16 hours after the induction.
Thus, our hypotesis was that, after i.v. transplantation, the cells homed in the lungs, where they
increased HGF production. Once released, HGF was able to reach the injury site through the blood
stream,  where  it  could  exert  its  pro-angiogenic,  trophic  and  immunomodulatory  activity.  The
overall effects were then translated in a higher myelin preservation that was reflected in a better
motor performance (Fig. 1).
Figure 1: Hypothesis motor recovery mechanisms. The increased levels of HGF mRNA and protein in lung sustained by
T-AFCs transplantation is detected in the injured organs. This binding is able to induce an increase of HIF-1α and VEGF
at the lesion site thus increasing angiogenesis. On the other site, HGF induces a lower macrophage infiltration at the
lesion site. Finally, HGF possesses intrinsic antiapoptotic properties: all together, this actions reflect in higher tissue
preservation with a consequent better motor performance. (Abbr. SC = spinal cord).
Preliminary studies revealed a sort of correlation between NG2 presence and HGF production. We
performed a gene silencing experiment in which we assessed HGF production after IL-1β and LPS
stimulations of T-cells from culture #7.30 previously silenced for NG2 (as controls were used wild-
type #7.30 cells and NT-cells from culture #9.1, that did not express the marker). Interestingly, we
observed a diminished HGF production in the silenced cells,  even though we were not able to find
out if the cells were less responsive to the inflammatory agents or suffered an impairement in HGF
production. Though the experiments were held as a pilot study, the results obtained suggest that
it might be useful to perform further studies, in order to assess if and how NG2 is linked to HGF
production.
The aforementioned results are very similar to the ones obtained by our group after neural stem
cells (NSC) and embryonic stem cells (ES) transplantation  (Bottai D. Et al., 2008, 2010) using the
same mouse model of spinal cord injury. Even though AF cells resulted less effective than NSC,
they are equivalent to ES in promoting motor recovery; however, it is important to consider that
AF cells were transplanted one week after injury, while NSC soon after the spine contusion. This
delay might explain the different scores obtained by AF-treated respect to NSC-treated mice. In all
cases, the different cells did not integrate into spine circuitry, being able to elicit therapeutical
effects  by  producing  trophic/antiapoptotic/antiinflammatory  factors.  The  observation  that  the
beneficial  and  therapeutic  effects  are  achieved  through  secretion  of  immune  modulatory  or
neurotrophic  paracrine factors has inspired an alternative outlook on the use of  stem cells  in
regenerative medicine (Drago D et al.,  2013).  During years, the perspective has changed from
integration into the damaged tissues, to a "bystander effect": in this case the transplanted cells
are  thought  to  act  as  "drugs  factories",  able  to  react  to  the  environment  releasing  bioactive
molecules (Martino G and Pluchino S, 2006; Fischbach MA et al., 2013; Pluchino S., et al 2013).
Very  recently,  Cossetti  and  colleagues  gave  new  insights  on  cellular  cross-talks,  identifying  a
mechanism of cellular signaling by which neural stem/precursor cells (NPCs) communicate with
the microenvironment via vesicles release (Cossetti C et al., 2014).
In perspective, being able to induce a "pluripotent state" or a neuralization of AF (Moschidou D et
al 2012), might represent a useful improvement of amniotic fluid cells properties, increasing their
therapeutic  potentiality,  as  it  could  affect  cells  homing  and/or  increase  neurotrophic  factors
production: NSC in fact, seems to possess a higher "pathotropism" towards the injured tissue, as it
is represented by nerve tissue (Butti E et al., 2014). Furthermore, a greater production of neural-
derived neurotrophic factors by neuralized AF cells, might improve their efficacy over target cells.
To conclude, amniotic fluid cells possess therapeutic activity when transplanted in our model of
spinal  cord  injury,  representing  an  a  tecnical  and  ethical  alternative  to  the  use  of  neural  or
embryonic stem cells.
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